Lista de obras - Paolo Denti - Dominio Público Uruguay

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

artículo científico publicado en 2018

A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture

artículo científico publicado en 2012

Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir

scientific article published on 18 February 2020

Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.

artículo científico publicado en 2017

Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice.

artículo científico publicado en 2012

Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis

article

Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests

artículo científico publicado en 2007

Characterizing multisegment foot kinematics during gait in diabetic foot patients

artículo científico publicado en 2009

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis

artículo científico publicado en 2017

Constructing a representative in-silico population for pediatric simulations: application to HIV positive African children

scientific article published on 08 December 2020

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets

artículo científico publicado en 2017

Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis

scientific article published on 18 February 2020

Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients

artículo científico publicado en 2021

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children

artículo científico publicado en 2016

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis

artículo científico publicado en 2017

Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy

artículo científico publicado en 2016

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

artículo científico publicado en 2017

Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

artículo científico publicado en 2016

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

artículo científico publicado en 2017

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients

artículo científico publicado en 2016

IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach

artículo científico publicado en 2010

Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches

artículo científico publicado en 2006

In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology

artículo científico publicado en 2015

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

artículo científico publicado en 2012

Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.

artículo científico publicado en 2017

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection

artículo científico publicado en 2019

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

artículo científico publicado en 2019

Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

artículo científico publicado en 2015

Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

artículo científico publicado en 2012

Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin

artículo científico publicado en 2013

Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients

artículo científico publicado en 2013

Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine

artículo científico publicado en 2012

Nonlinear mixed effects to improve glucose minimal model parameter estimation: a simulation study in intensive and sparse sampling

artículo científico publicado en 2009

Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV

artículo científico publicado en 2014

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

artículo científico publicado en 2016

Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor

artículo científico publicado en 2014

Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.

artículo científico publicado en 2017

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

artículo científico publicado en 2015

Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis

artículo científico publicado en 2017

Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.

artículo científico publicado en 2017

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection

artículo científico publicado en 2014

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure

scientific article published on 27 March 2019

Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa

artículo científico publicado en 2013

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children

artículo científico publicado en 2016

Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis

scientific article published on 21 February 2020

Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV

scientific article published on 21 February 2020

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa

artículo científico publicado en 2015

Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring

artículo científico publicado en 2012

Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone

artículo científico publicado en 2020

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.

artículo científico publicado en 2012

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

artículo científico publicado en 2014

Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis

scientific article published on 23 November 2020

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants

artículo científico publicado en 2017

Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines

artículo científico publicado en 2012

Response to "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".

artículo científico publicado en 2017

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

artículo científico publicado en 2011

The disposition index: from individual to population approach

artículo científico

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children

artículo científico publicado en 2016

The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals

artículo científico publicado en 2013

Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa

artículo científico publicado en 2015

Lista de obras de Paolo Denti

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture

Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir

Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.

Antimalarial and anticancer activities of artemisinin-quinoline hybrid-dimers and pharmacokinetic properties in mice.

Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis

Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests

Characterizing multisegment foot kinematics during gait in diabetic foot patients

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis

Constructing a representative in-silico population for pediatric simulations: application to HIV positive African children

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets

Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis

Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis

Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients

IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach

Identification of IVGTT minimal glucose model by nonlinear mixed-effects approaches

In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.

Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin

Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients

Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine

Nonlinear mixed effects to improve glucose minimal model parameter estimation: a simulation study in intensive and sparse sampling

Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients

Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor

Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.

Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania

Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis

Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection

Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure

Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children

Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis

Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV

Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa

Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring

Population pharmacokinetics of cycloserine, and pharmacokinetic/pharmacodynamic target attainment, in MDR-tuberculosis patients dosed with terizidone

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants

Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines

Response to "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".

The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

The disposition index: from individual to population approach

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children

The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals

Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa